Table 2. Longitudinal Lung Function Assessment of Cohort.
| Time | Variable | Cases | N | Controls | N | p |
| Pre-9/11 * | FEV1% | 88(81–96) | 70 | 104(92–113) | 123 | <0.001 |
| FEV1/FVC | 81.7(78–86) | 70 | 84.9(81–88) | 123 | 0.001 | |
| MME * | FEV1% | 78(71–89) | 70 | 93(84–99) | 123 | <0.001 |
| FEV1/FVC | 81.4(76–86) | 70 | 83.8(80–87) | 123 | 0.016 | |
| SPE | FEV1% * | 72(66–75) | 70 | 96(88–104) | 123 | <0.001 |
| FEV1/FVC * | 71.1(65–77) | 70 | 77.1(73–81) | 123 | <0.001 | |
| BDR * % | 15(7–29) | 46 | 5(2–8) | 46 | <0.001 | |
| BDR≥12%, (N,%) | 30(65) | 46 | 10(22) | 46 | <0.001 | |
| MCT slope * | 0.24(0.06–1.78) | 34 | 0.05(0.03–0.11) | 102 | 0.001 | |
| PC20≤10 mg/mL, (N,%) | 17(50) | 34 | 19(19) | 102 | <0.001 | |
| TLC% * | 96(83–106) | 47 | 103(98–109) | 53 | 0.002 | |
| RV,% Pred * | 130(109–157) | 47 | 123(111–140) | 53 | 0.525 | |
| DLCO% * | 96(85–107) | 46 | 107(101–116) | 52 | <0.001 | |
| VA% * | 83(75–89) | 35 | 94(87–101) | 43 | <0.001 | |
| DLCO/VA * | 122(113–134) | 36 | 117(105–122) | 40 | 0.038 | |
| Nodule, (N,%) | 18(45) | 40 | 25(39) | 64 | 0.550 | |
| Air Trapping, (N,%) | 22(55) | 40 | 27(42) | 64 | 0.203 | |
| BWT, (N,%) | 13(33) | 40 | 23(36) | 64 | 0.833 |
*
Median (IQR).
FEV1, Forced Expiratory Volume in one second; FVC, Forced Vital capacity; BDR, Bronchodilator Response; MCT, Methacholine Challenge Testing; PC20, Provocative concentration of methacholine that results in a 20% drop in FEV1; TLC, Total Lung Capacity; RV, Residual Volume; DLco, Diffusing Capacity of the Lung for Carbon Monoxide; VA, Alveolar Ventilation; BWT, Bronchial Wall Thickening.